{"id":17975,"date":"2014-05-09T02:30:00","date_gmt":"2014-05-09T00:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/farmaci-oncologici-troppo-cari-clerico-cipomo-industria-sia-alleata-dei-pazienti-2\/"},"modified":"2014-05-09T02:30:00","modified_gmt":"2014-05-09T00:30:00","slug":"farmaci-oncologici-troppo-cari-clerico-cipomo-industria-sia-alleata-dei-pazienti-2","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaci-oncologici-troppo-cari-clerico-cipomo-industria-sia-alleata-dei-pazienti-2\/","title":{"rendered":"Overpriced oncological drugs, Clerico (Cipomo): industry should be an ally of patients"},"content":{"rendered":"

\u00abThe pharmaceutical industry must become the patient's ally, while it runs the risk of being the "counterpart" that demands a hefty and poorly understood tax. The survival of cancer patients continues to increase thanks to the availability of new drugs. Small increases that add up, but at costs that are becoming unsustainable for any health system \u00bb. This is the opinion of Mario Alberto Clerico, secretary of the Italian college of leading hospital medical oncologists (Cipomo), who is not surprised by the complaint from the Institute for healthcare informatics (Ims) according to which, in the United States, many patients have to give up treatment. The insane cost of some oncological drugs \u2013 which for some treatments even reached 100,000 dollars per session \u2013 had already sparked the protest of over one hundred US oncologists last year who had pointed the finger at the profit logic of pharmaceutical companies.
\u00abThe pharmaceutical industry has to bear enormous costs to get to produce an effective drug. \u2013 admits Clerico \u2013 On the other hand, however, research is often planned according to profit criteria and the results do not necessarily coincide with the patients' needs. Sometimes very expensive drugs come onto the market that will benefit very few people and sometimes this advantage is given by an increase in survival of a few days. Can we afford it? Is it justifiable to commit huge sums of money for small benefits for a few people?\u00bb
Secretary Cipomo points out that for some time now clinicians and patient associations have been asking to be involved immediately in the definition of a research project and in the decision on the real usefulness of a new drug. \u201cPatients have precise expectations. As Rita Levi Montalcini said, \u201cit is better to add life to days than days to life\u201d. This would make it possible to reduce research costs for drugs of little use (for patients), to commit resources where there is a greater need".
<\/font><\/span>Renato Torlaschi<\/p>\n

<\/span><\/i><\/strong><\/p>\n

Friday, 09 May 2014 \u2013 <\/span><\/i>Doctor<\/span>33<\/p>\n

<\/font><\/span><\/b><\/p>\n

Global anti-cancer spending at $91 billion in 2013<\/p>\n

<\n<\/p>","protected":false},"excerpt":{"rendered":"

«L’industria farmaceutica deve diventare l’alleata dei pazienti, mentre rischia di essere la “controparte” che esige un esoso e poco compreso balzello. La sopravvivenza dei malati oncologici continua ad aumentare grazie anche alla disponibilità di nuovi farmaci. Piccoli aumenti che si sommano, ma a costi che stanno diventando insostenibili per qualsiasi sistema sanitario». È l’opinione del …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-17975","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=17975"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17975\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=17975"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=17975"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=17975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}